AMG 510 Shows Activity beyond NSCLC
- PMID: 32540954
- DOI: 10.1158/2159-8290.CD-NB2020-061
AMG 510 Shows Activity beyond NSCLC
Abstract
The latest results from the CodeBreak 100 trial evaluating AMG 510 indicate that this first-in-class KRAS inhibitor, having shown promise in non-small cell lung cancer, is modestly active in several other types of solid tumors, including colorectal cancer.
©2020 American Association for Cancer Research.
Comment on
-
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.Cancer Discov. 2020 Aug;10(8):1129-1139. doi: 10.1158/2159-8290.CD-20-0187. Epub 2020 May 19. Cancer Discov. 2020. PMID: 32430388 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
